Showing 1251-1260 of 1371 results for "".
- Modern Aesthetics® Announces New Tweet Chat Series -- #RealDealAestheticshttps://modernaesthetics.com/news/modern-aesthetics-announces-new-tweet-chat-series-realdealaesthetics/2472073/Modern Aesthetics® magazine is launching a new Tweet chat series -- #RealDealAesthetics -- featuring New York City dermatologist Gary Goldenberg, MD and Charleston, SC dermatologist Todd E. Schlesinger, MD. The first Tweet chat focuses on filler selection in a r
- Evolus Appoints Michael Mazen Jafar Chief Marketing Officerhttps://modernaesthetics.com/news/evolus-appoints-michael-mazen-jafar-chief-marketing-officer/2472075/Evolus, Inc. has expanded its management team with the appointment of Michael Mazen Jafar as Chief Marketing Officer. Mr. Jafar joins Evolus from Allergan where he most recently served as Vice President, Medical Aesthetics. At Allergan Mr. Jafar led the commercial launch of Juve
- Xact Scores Best of Hot Topics at ASAPS 2018https://modernaesthetics.com/news/xact-scores-best-of-hot-topics-at-asaps-2018/2472078/Cypris Medical, Inc.’s Xact technology took home the “Best of Hot Topics” award at the American Society for Aesthetic Plastic Surgery (AS
- Revance Vet Tapped as New Evolus CFOhttps://modernaesthetics.com/news/revance-vet-tapped-as-new-evolus-cfo/2472086/Lauren Silvernail is the new Chief Financial Officer and Executive Vice President, Corporate Development at Evolus, Inc. Silvernail joins Evolus from Revance Therapeutics where she most recently served as Chief Financial Officer and Chief Business Officer. Prior to her time at Revance The
- FDA Says No to Evolus' Botox Rivalhttps://modernaesthetics.com/news/fda-says-no-to-evolus-botox-rival/2472089/The U.S Food and Drug Administration did not approve DWP-450, Evolus Inc's rival product to Allergan Plc's Botox, due to chemistry and manufacturing issues. As a result, the company pushed its estimate for the launch of the drug to the spring of next year. Read more
- Cutera Marks 20 Years of Innovationhttps://modernaesthetics.com/news/cuter-marks-20-years-of-innovation/2472102/Cutera, Inc. is celebrating 20 years of best-in-class product innovation with continued commitment to the industry and its providers, marking the milestone at the Annual Meeting of the American Society for Laser Medicine and Surgery in Dallas. In conjunction with the 20th&nbs
- Jacob Chacko, MD Joins Bonti's Board of Directorshttps://modernaesthetics.com/news/jacob-chackomd-joins-bontis-board-of-directors/2472135/Jacob Chacko, MD has joined Bonti’s Board of Directors. Dr. Chacko has served as the Chief Financial Officer of Ignyta, Inc. since May 2014. At Ignyta, he leads multiple functions, including Finance, Accounting, Investor Relations, Comm
- Cynosure's TempSure™ Envi Set to Debut at 2018 AAD Meetinghttps://modernaesthetics.com/news/cynosures-tempsure-envi-set-to-debut-at-2018-aad-meeting/2472144/Hologic's Cynosure division is launching TempSure™ Envi – an FDA-cleared advanced radiofrequency device. TempSure™ Envi heats the deep layers of skin to regenerate collagen and
- New From Cutera: Juliet and Secret RFhttps://modernaesthetics.com/news/new-from-cutera-juliet-and-secret-rf/2472149/Cutera has introduced two new devices to its laser and energy-based device offerings: Juliet™ and Secret RF
- Investigational Neurotoxin Achieves 6-Month Duration in Phase 3: Revancehttps://modernaesthetics.com/news/investigational-neurotoxin-achieves-6-month-duration-in-phase-3-revance/2472157/Revance Therapeutics’ next-generation neuromodulator DaxibotulinumtoxinA for Injection (RT002) delivered positive top-line results in alleviating moderate-to-severe glabellar lines in two pivotal SAKURA Phase 3 trials with duraction of effect up to 6 months. RT002 appeared generally safe an